Thank you, Steve, and good morning, everyone. I'm pleased to report that Revvity delivered strong results in the second quarter with pro forma organic growth of 3%, resulting in total revenue being above the high end of our expectations. Our pro forma adjusted earnings per share of $1.41 was well above the high end of our guidance due to better-than-expected underlying operating performance, tax planning timing and the unanticipated contribution of tariff refunds we received in the quarter, which Max will touch on more in a bit. These results reflect the continued strength and resilience of our Diagnostics franchise, the third consecutive quarter of improving conditions across our pharma and biotech end markets, growing customer demand for tools that enable AI-driven science and the continued momentum of our Signals software business. Given the stronger performance and our improved optimism for the second half, we are raising our pro forma guidance for organic growth, adjusted operating margin and adjusted EPS for the full year, which Max and I will provide additional detail on in a bit. Before I provide more detail on the operational progress we are making, I want to share a brief update on the status of the divestiture of our China immunodiagnostics business, which we first announced last quarter. We have now signed a definitive agreement with the buyer on terms consistent with our initial expectations, and we continue to anticipate the transaction closing by the end of 2027. This divestiture is a deliberate strategic decision as China has represented a structurally more challenging environment for this part of our business of late, and we are confident this transaction allows us to sharpen our focus on the end markets where our differentiated capabilities generate the highest and most durable returns for our shareholders. While our reported GAAP results will continue to include the contribution from this business until the transaction is completed next year, all of our non-GAAP and organic performance, commentary and guidance are provided on a pro forma basis, which excludes the immunodiagnostics business in China that we have agreed to divest. Now turning to our end markets. I'm increasingly encouraged by what we continue to see. The gradual improvement in demand from our pharma and biotech customer base that we began to observe in recent quarters continued into the second quarter, and we are now seeing tangible signs of a more constructive spending environment. In particular, we are seeing a definitive and progressively larger increase in orders directly related to AI, reflecting demand from both traditional pharma and biotech customers as well as emerging demand from non-traditional customers that have not historically purchased from us. These organizations are building AI-driven drug discovery platforms and are seeking capabilities that sit squarely within Revvity's portfolio. That is why we are especially well positioned, because AI may accelerate hypothesis generation, but those hypotheses still need to be tested, validated and advanced through real-world biological data generation, lab-based experimentation and software-enabled collaboration. Together, this improving demand from existing customers and new demand from customers outside of our historical base contributed to a higher-than-normal level of instrument backlog exiting the second quarter, positioning us very well as we enter the second half of the year. While we have touched on this over the past several quarters, demand for our high-content screening instruments, particularly our recently introduced new flagship instrument, the Opera Phenix OptIQ, remains extremely robust with continued double-digit growth year-over-year despite more difficult year ago comparisons. Demand for high-content screening further accelerated during the second quarter with order velocity outpacing near-term production capacity despite dedicating additional resources as the quarter progressed to support customer demand. As a result, while we may have left some further incremental upside on the table in the quarter, it positions us even better as we move into the third quarter and back half of the year. It is important to note that this build-out by our customers of additional capacity will also result in future improvements in demand for our related high-content screening reagents. Because high content screening is commonly used by customers to both generate new data and to validate existing hypotheses, it plays an increasingly important role in AI-driven discovery workflows, where lab-generated insights can be fed back into AI models over time. This acceleration in high content screening demand is a tangible example of the AI adoption cycle I discussed with you last quarter beginning to play out. At that time, I described how we expect AI to move from solely being in an infrastructure build-out phase to eventually a value creation phase where the real opportunity comes from generating, validating and translating new biological data. We are now beginning to see that dynamic show up directly in customer behavior as AI enables customers to identify and design more therapeutic compounds and molecules that still need to be tested, screened and validated in the lab. That is where Revvity is especially well positioned, because the need for high-quality biological data, physical validation and integrated scientific workflows plays directly to our core strengths. This concept where AI models become part of the experimental cycle itself, continuously learning from results, suggesting next steps and compressing the time between hypothesis and insight, but importantly, generating more unique data than ever possible in the past is increasingly being referred to by customers as a Lab-in-the-Loop workflow. Revvity's instruments and reagents generate the data. Signals One manages and structures it and our recently released Signals AI capabilities and our newly introduced Anthropic MCP connector now allows scientists to close that loop in ways that were simply not possible before. These examples highlight how Revvity helps power scientific intelligence as we support customers throughout this new discovery process, reinforcing why we are one of the best positioned companies in the entire industry to benefit from the AI-driven transformation of pre-clinical R&D that is only just beginning to take place. Against this backdrop, our Signals software business remains a critical part of how we enable customers to manage and apply scientific data across their workflows. In the second quarter, Signals performed in line with our expectations against a very difficult year ago comparison with organic revenue declining approximately 20% year-over-year. We continue to expect a return to strong double-digit growth in the second half of the year in our software business as its APV continues to grow in the double digits. As you have seen from our many new product announcements so far this year, the level of innovation in this business is robust and has only begun accelerating. Our large molecule workflow offering, BioDesign, is now commercially available and beginning to gain traction. Our AI models as a service platform, Synthetica, began rolling out to initial beta customers last month and our novel workflow coordination layer offering, which spans discovery through manufacturing, LabGistics remains on track to be released later this year. In the meantime, we also recently launched Signals AI, which embeds leading LLM capabilities throughout our Signals platform, allowing users to leverage AI capabilities within the core platform itself where their proprietary data already exists. In early July, we also announced a new connector with Anthropic, enabling customers to use their data along with other outside programs and data sets directly within Claude and Claude Science itself. These 2 new capabilities are complementary to each other and both expand the functionality of the core Signals platform, while creating greater stickiness, driving increased retention along with adding new consumption-based revenue streams over time. Finally, just 2 weeks ago, we announced a new initiative called Signals for Startups, which is a new commercial program designed to make our Signals platform accessible to even the smallest of biotechs. This allows these customers to adopt and incorporate our Signals platform with its predefined workflows right from the outset of their corporate journey, so they can more easily scale as their businesses take off. I look forward to sharing more with you on all the exciting developments occurring within Signals at our upcoming Investor Day on November 13 in New York City. The strength across our portfolio is also reflected in our Diagnostics business, which again delivered exceptional performance. Overall, Diagnostics grew 11% organically in the quarter, a further step-up from the high single-digit organic growth we saw from the segment in the first quarter. It is important to highlight that this strong performance was broad-based and remains impressive even when excluding the incremental contribution from our Genomics England sequencing contract, which also continues to perform well. The consistency and durability of this franchise continues to be a defining strength of Revvity's overall business model as both reproductive health and immunodiagnostics performed well, driven by ongoing strength in newborn screening and strong growth in immunodiagnostics outside of China. Reproductive health again grew in the mid-teens and immunodiagnostics growth outside of China accelerated into the high single digits, despite continued latent TB pressures. As it pertains to our ongoing corporate transformation, I'm proud of the progress we are making with strong execution in a number of areas. First, the integration of the recently acquired ACD/Labs software business is progressing faster than anticipated with early momentum in synergy realization and product interoperability across the combined offerings. Second, we continue to drive our ongoing operational efficiency initiatives with implementation well underway. These initiatives will benefit us more here in the second half as well as into next year. We are also doing a good job managing our balance sheet as we generated significant cash in the quarter with exceptional cash flow conversion of our adjusted net income of 117%. In mid-July, we also paid off a EUR 500 million note we had coming due, which we expect will result in our gross leverage being below 3x by the end of the year and our net leverage approaching 2x overall. Finally, I'm proud to share that we recently published our 2026 annual Impact Report. This report reflects the meaningful progress Revvity has made across our environmental, social and governance commitments, including continued absolute year-over-year reductions in our emissions, improvement in our internal employee mobility metrics and our first-ever disclosure of our material Scope 3 emissions, which will allow us to have our targets verified by SBTi in the coming months. The nature of our products inherently enables Revvity to make a meaningful positive contribution to society on a global scale, but we also remain committed to operating, innovating and creating long-term value in a sustainable way, while also providing attractive opportunities for our employees. As we look ahead to the second half of the year, given the strong diagnostic trends we have seen so far, when combined with what appears to be continuing improvement in pharma and biotech end market conditions, we are now more optimistic compared to 90 days ago. Consequently, we are now expecting total company organic growth this year of 4% to 5%, up from our prior 3% to 4% outlook. We expect to be able to generate adjusted operating margins of approximately 28.7% this year due to the stronger organic growth we now expect for the year, combined with the impact of the tariff refunds we've received, which is being partially offset by incremental reinvestments we are making in our strategic initiatives, supply chain and in our people, which should allow us to capitalize on the end market recovery that we believe is now underway. This all results in our updated full year adjusted EPS outlook to now be in a range of $5.30 to $5.40, which is up $0.10 from our prior guidance. So in closing, the second quarter reinforced that Revvity is in a strong and increasingly differentiated position. Our Diagnostics business continues to perform extremely well with consistency and resilience. Our Life Science end markets are showing signs of improvement and the investments we've made internally over the last few years are beginning to bear fruit, as we are delivering new innovations to our customers at an accelerating rate. We are extremely well positioned to deliver over the remainder of the year, while capitalizing on the new opportunities presenting themselves as preclinical science is redefined in the new AI world. I believe that the true potential of Revvity is beginning to be realized and shine through. With that, I will now turn the call over to Max.

Thanks, Prahlad, and good morning, everyone. We are clearly seeing improving momentum across the business, which is evident in both our performance in the quarter and our stronger outlook for the full year. Both of our Diagnostic businesses continued to perform extremely well and improving activity from our pharma and biotech customers supported solid Life Sciences performance and increased backlog heading into the second half of the year. As discussed, it is exciting to see tangible and accelerating signs of demand from customers tied to their increasing data generation needs as AI unlocks new ways to operate preclinical R&D labs. We are increasingly optimistic that not only is Revvity extremely well positioned to capitalize on the fundamental shift in how preclinical R&D is conducted, but also that we are currently only seeing the very initial stages of that transformation. We continue to execute very well in the quarter from an operational standpoint as evidenced by our margin, earnings and cash flow performance, even when excluding the $16 million of tariff-related refunds we received in the quarter, which drove about half of the adjusted EPS upside, our pro forma adjusted operating margins were still above the 27% assumption in our guidance. With what appears to be an improvement in end market conditions underway, we have chosen to reinvest about half of this one-time benefit back into our strategic initiatives, supply chain and people to ensure we are well positioned to capitalize on the opportunities we see emerging as we head into the second half of the year and into 2027. Given the significant actions we've taken over the last few years to mitigate and offset the various pressures we faced without having to resort to passing on material price increases to our customers, we are excited we now have this opportunity to further invest in the business to drive even stronger performance over the longer term, while still being able to deliver upside to our financial commitments for this year. Finally, it was great to see that we executed a definitive agreement to divest our immunodiagnostics business in China on terms consistent with our initial expectations. With separation planning already well underway, we and the buyer are well positioned to complete the transaction by the end of 2027. Now turning to the specifics of our second quarter performance. As a reminder, given the pending divestiture of our immunodiagnostics business in China, all of the following commentary and our updated guidance is provided on a pro forma basis, which excludes the impact of this business we expect to divest next year. Overall, we generated total revenue of $711 million in the quarter, resulting in strong 3% organic growth, which was slightly above the high end of our guidance. FX had an immaterial impact on reported growth and our recent software acquisition, ACD/Labs, contributed approximately 75 basis points to growth, which was in line with our expectations. As it relates to our P&L, we delivered strong operational performance in the quarter, while also benefiting from the impact of tariff refunds. Overall, our adjusted operating margins were 29.3% in the quarter, well above our 27% outlook. While the majority of this outperformance was driven by the tariff refunds, operationally, our margins also came in better than we had anticipated. Looking below the line, our adjusted net interest and other expenses were $22 million in the quarter, in line with our expectations. Our adjusted tax rate was 16%, a couple of hundred basis points lower than expected due to the timing of discrete items being realized in the quarter that were previously anticipated to occur in the fourth quarter. This change is just timing related as our full year tax rate outlook of 18% is unchanged. We averaged 111.6 million diluted shares in the quarter as we continue to benefit from our share repurchase activity over the last 12 months. Following the end of the quarter, in mid-July, we retired the EUR 500 million note we had maturing, which resulted in a meaningful drop in our gross leverage overall. Our pro forma adjusted earnings per share in the quarter was $1.41, which was well above the high end of our guidance due to the stronger top line, better-than-expected underlying margin performance, tax timing and the tariff-related refunds. To quantify the moving pieces for you, approximately half of the upside in the quarter was from the tariff refunds, roughly 1/3 was from the lower tax rate we saw, which will have an offsetting impact in the fourth quarter, and the remainder was from the combination of stronger revenue and underlying operating margins. Moving beyond the P&L, we generated robust free cash flow of $184 million in the quarter, resulting in an outstanding 117% conversion of our adjusted net income. On a year-to-date basis, we've now generated nearly $300 million in free cash flow with a conversion rate of 108% of our adjusted net income. Our balance sheet remains strong as we finished the quarter with a net debt-to-adjusted EBITDA leverage ratio of 2.5x. As mentioned, we retired our Eurobond in July and are still targeting a gross leverage ratio of below 3x as we exit the year. Following this recent repayment, our outstanding debt stack continues to remain very well positioned as 100% of our long-term debt remains fixed rate with a weighted average interest rate of 2.3% and a weighted average maturity out another 6 years. I will now provide some commentary on our second quarter business trends, which are also highlighted in the quarterly slide presentation on our Investor Relations website. Again, these results are on a pro forma basis and exclude our immunodiagnostics business in China and are comparable to the guidance we provided 90 days ago. The 3% growth in total company organic revenue in the quarter was comprised of 11% organic growth in our Diagnostics segment and a 3% organic decline in our Life Sciences segment. Geographically, Europe continued its double-digit growth. APAC grew in the low single digits, and the Americas experienced a low single-digit decline due to software comps and continued latent TB pressures. From a segment perspective, Life Sciences generated revenue of $359 million in the quarter. This was down 2% on a reported basis and 3% on an organic basis. From a business perspective, the decline in Life Sciences was driven by the approximately 20% decline in our Signals software business as we had expected due to contract timing and comps from a year ago. Outside of these comp dynamics, the business continued to perform well as its APV again grew in the double digits and ARR was in the mid-20s. Life Sciences Solutions grew low single digits organically in the quarter with both reagents and instrumentation growing in that range as stronger instrument performance was held back by timing of shipments, which is leading to the stronger backlog we have entering the second half of the year. From a customer perspective, sales into pharma and biotech declined in mid-single digits due to difficult comp we had in our software business in the quarter. Excluding software, sales into pharma and biotech grew in the low single digits. As software returns to stronger growth in the second half of the year and as more of the instrument orders translate to revenue, we expect to see improved performance from this customer base over the remainder of the year. Sales to academic and government customers were down low single digits year-over-year due to software-related year ago comparisons. In our Diagnostics segment, we generated $352 million of revenue in the quarter, which was up 12% on a reported basis and 11% on an organic basis. From a business perspective, both our immunodiagnostics and reproductive health businesses performed exceptionally well and grew above our expectations. Immunodiagnostics grew in the high single digits organically in the quarter with broad-based strength. Reproductive health again grew in the double digits organically as it benefited from another strong quarter in newborn screening and from the incremental contribution from our work with Genomics England. Now moving to our updated guidance for the year. Again, our updated guidance is on a pro forma basis, excluding the business we are planning to divest as this is the most appropriate way to view the company and its performance going forward. Overall, many things appear to be moving in the right direction across the business. Right now is our organic growth, operating margins and EPS, all came in solidly above our expectations in the second quarter, even when excluding the impact of the tariff refund. Given this momentum, we are now more optimistic about our expected performance over the remainder of the year as compared to a quarter ago. We now expect our organic growth for the year to be in the 4% to 5% range, up from our prior 3% to 4% outlook. FX is still expected to contribute approximately 50 basis points for the full year, while the ACD/Labs acquisition is still on track to add another 75 basis points to our revenue growth this year. We expect this to now result in our 2026 pro forma total revenue being in the range of $2.83 billion to $2.86 billion. We now anticipate our pro forma adjusted operating margins this year to be 28.7%, which is up 30 basis points from our prior guidance. This improved outlook is due to two primary drivers. First, the impact from tariff refunds, partially offset by reinvestments we are making; and second, leverage from our stronger organic growth outlook for the year, of which a portion was realized in the second quarter. We continue to make good progress on our major cost initiatives and still expect their impact to be realized starting here in the third quarter. As we have already received the majority of the tariff refunds we applied for in the second quarter, any additional refunds we may receive are anticipated to be immaterial to our results overall. We still anticipate net interest and other expense to be approximately $90 million, and our full year adjusted tax rate assumption also remains unchanged at approximately 18% as the favorability we experienced in the second quarter was timing related and is expected to be offset in the fourth quarter. We also still expect our diluted average share count to be approximately 112 million. This all results in us now expecting that our adjusted earnings per share this year will be in the range of $5.30 to $5.40, up $0.10 from our prior outlook. This $0.10 increase to our full year adjusted EPS guidance is roughly half from the net impact of tariff refunds, offset by planned reinvestment spending and half from stronger revenue and underlying operating margins compared to our prior outlook as our full year tax rate remains the same. For the third quarter, we expect our organic growth to be in the 4% to 6% range. Assuming FX rates as of the end of June and the incremental contribution from the ACD/Labs acquisition, this puts our expected revenue for the third quarter in the range of $685 million to $700 million. We continue to look for approximately 29% pro forma adjusted operating margins in the third quarter, which is unchanged from our prior outlook despite some incremental reinvestment spending now being planned. We expect net interest and other expense to be approximately $23 million and our adjusted tax rate to be 19%. This should all result in our pro forma adjusted EPS in the third quarter to be approximately 24% of our full year outlook. In closing, we had a strong second quarter with increasing momentum as we head into the second half of the year. It appears that our pharma and biotech customers are beginning to return to more normalized patterns, while increasing AI-related work is creating incremental demand, which did not exist in the past. Our Diagnostic business performance remains robust and software continues to grow its annualized portfolio value in the double digits with a return to robust organic growth starting this quarter. Our execution on our operational initiatives remain strong and our recent capital deployment and portfolio rationalization actions will benefit us over the longer term. As Prahlad mentioned, we believe the true potential of what Revvity has become is only now beginning to be realized, while we know that we have a lot of additional opportunity still in front of us. With that, operator, we would now like to open up the call for questions.